Menu
Close
.svg)
During a recent visual aid test my colleagues and I were conducting for a pharma client, a sugar pill appeared to be putting up rather respectable numbers.
We were evaluating physician reactions to an IVA for an investigational insomnia medication, although the same dynamic could readily surface with an analgesic or antidepressant. The active treatment, Product X, produced a statistically significant improvement over placebo, but many of our physician respondents were less focused on the p-value than the graph. To them, the treatment advantage looked modest, the separation between the arms was not especially dramatic and patients receiving placebo had improved substantially.
More than one physician offered essentially the same reaction, partly in jest but only partly: “Perhaps I should just prescribe the placebo.”
I suspect I am not the only moderator in pharma marketing research who has heard some version of this quip. One physician saying it may simply be enjoying the sound of his own punchline. When several say it independently, however, the joke has become a finding.
The physicians certainly were not disputing the statistical analysis. They were questioning whether Product X’s apparently incremental benefit looked meaningful enough to change their prescribing behavior. On the face of it, that was fair criticism. It also left the marketing team with a familiar conundrum: how do you explain a conspicuous placebo response without sounding defensive, patronizing or as though you are trying to talk the doctor out of what is plainly visible?
The word placebo comes from the Latin for “I shall please.” Even its etymology sounds mildly promotional and potentially subject to an MRL review.
Yet the placebo has an attribution problem. Clinical discussions routinely use placebo response and placebo effect interchangeably, although they describe different things.
The placebo response is the total change observed among patients assigned to placebo. It tells us what happened, but not why. The narrower placebo effect refers to the psychobiological influence of expectation, previous experience and conditioning. Patients have spent a lifetime associating pills, physicians and clinical rituals with relief. Those associations can affect subjective experience and, in some settings, measurable physiology. “Psychological” is not a euphemism for imaginary.
But the placebo effect is only one ingredient in the larger placebo response. Patients may also improve because symptoms fluctuate, trial participation changes behavior, clinical attention increases, concomitant interventions help or an unusually severe period is followed by a more typical one. Measurement variability and reporting bias can join the procession.
Regression to the mean is especially important. Patients often qualify for a trial precisely because their symptoms are unusually troublesome at baseline. Some will look better when reassessed even if nothing therapeutically meaningful has occurred. The inert tablet just happens to be nearby and, like an executive being hired shortly before an improvement in quarterly earnings, receives an inordinate share of the credit.
A conventional two-arm clinical trial cannot apportion the improvement among these causes. That generally requires a no-treatment group. Most industry trials were designed to answer a different question: what additional benefit did the medicine produce beyond everything experienced by both randomized groups?
High placebo responses are particularly common when endpoints are subjective, symptoms fluctuate and expectations can influence experience. Insomnia offers all three.
A meta-analysis of 32 insomnia studies involving 3,969 participants found improvement in placebo groups across sleep onset, total sleep time, wakefulness after sleep onset and sleep efficiency. Changes in the placebo groups were equivalent to nearly 64% of those observed in the drug groups. That figure is eye-catching, but it does not mean inert pills generated 64% of the pharmacological benefit. It describes parallel improvement; it does not assign causality.
Other categories furnish equally intriguing examples. In osteoarthritis and chronic pain, sham injections, sham physical therapy and even sham surgery have sometimes produced substantial improvements. Open-label placebos, i.e., tablets patients are explicitly told contain no active medicine, have shown benefits in conditions including irritable bowel syndrome, lower-back pain and premenstrual symptoms. Nocebo research provides the disquieting mirror image: patients receiving placebo may report adverse events resembling those associated with the active drug they might be receiving.
The placebo is therefore neither nothing nor a clandestine medicine. It is an elaborate admixture of biology, psychology, context, natural history and statistical happenstance.
Knowing this is intellectually satisfying. It is not yet an actionable commercial response. Brand teams need to translate placebo literacy into a disciplined communications strategy, both before and after the physician raises the objection.
I would suggest six practical moves (while at the same time being keen to hear about others' experiences):
An appropriate field response might sound like this: “You’re right, doctor, the placebo group improved substantially. That response includes the treatment-expectation effect, but also natural fluctuation, study participation and regression to the mean. Because those influences were present in both randomized groups, the difference between them estimates what [Product X] added. The relevant question is whether that additional benefit matters for this patient.”
That explanation takes less than a minute and does not suddenly beam the physician back to college statistics. It acknowledges the evidence, respects the question and returns the discussion to clinical judgment.
The placebo is not the adversary of the medicine, and it should not be disparaged as though it had committed an evidentiary misdemeanor. But neither should it receive credit for every improvement that occurred in its general vicinity.
When a control arm steals the show, the strategic objective is not to drag it offstage. It is to help physicians understand precisely what they saw, and what your drug, Product X, contributed beyond it.
_____
